Literature DB >> 12730871

Frequent mutations of hepatocyte nuclear factor 1 in colorectal cancer with microsatellite instability.

Pierre Laurent-Puig1, Olivier Plomteux, Olivier Bluteau, Franck Zinzindohoué, Emmanuelle Jeannot, Karin Dahan, Alex Kartheuser, Caroline Chapusot, Paul-Henri Cugnenc, Jessica Zucman-Rossi.   

Abstract

BACKGROUND & AIMS: The TCF1 gene encoding hepatocyte nuclear factor 1 alpha (HNF1), a transcription factor germline mutated in patients with maturity-onset diabetes of the young type 3, was recently found to be frequently inactivated by biallelic alterations in liver adenoma and in rare hepatocellular carcinomas. The impact of HNF1 in colorectal carcinogenesis has not been studied until now. Colorectal cancer is characterized by the existence of different molecular mechanisms known as microsatellite stable or unstable tumors.
METHODS: At first, a series of 10 adenomas and 29 colon cancers regardless of microsatellite instability status were screened for TCF1 mutations on the entire coding sequence.
RESULTS: Three mutations in microsatellite instability high (MSI-H) tumors were found in the exon 4 polymorphic poly-cytosin (C)(8) or (C)(9) tract and consisted of a cytosin deletion at position 291. To further characterize the prevalence of TCF1 mutations in the subgroup of MSI-H tumors, 52 additional MSI-H samples were screened for exon 4 alterations; 23% of MSI-H tumors (95% confidence interval, 14%-36%) were found to harbor frameshift at the poly-cytosin tract. The (C)(9) allele was significantly more frequently mutated than the (C)(8) allele (22% vs. 8%; P = 0.03), showing a higher instability of the longer repetition.
CONCLUSIONS: These results show a role for HNF1 in MSI-H colorectal carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12730871     DOI: 10.1016/s0016-5085(03)00268-3

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  4 in total

1.  Hepatocellular adenoma displaying a HNF1alpha inactivation in a patient with familial adenomatous polyposis coli.

Authors:  Emmanuelle Jeannot; Dominique Wendum; François Paye; Najat Mourra; Claudia de Toma; Jean-François Fléjou; Jessica Zucman-Rossi
Journal:  J Hepatol       Date:  2006-10-04       Impact factor: 25.083

2.  Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer.

Authors:  Donghui Li; Eric J Duell; Kai Yu; Harvey A Risch; Sara H Olson; Charles Kooperberg; Brian M Wolpin; Li Jiao; Xiaoqun Dong; Bill Wheeler; Alan A Arslan; H Bas Bueno-de-Mesquita; Charles S Fuchs; Steven Gallinger; Myron Gross; Patricia Hartge; Robert N Hoover; Elizabeth A Holly; Eric J Jacobs; Alison P Klein; Andrea LaCroix; Margaret T Mandelson; Gloria Petersen; Wei Zheng; Ilir Agalliu; Demetrius Albanes; Marie-Christine Boutron-Ruault; Paige M Bracci; Julie E Buring; Federico Canzian; Kenneth Chang; Stephen J Chanock; Michelle Cotterchio; J Michael Gaziano; Edward L Giovannucci; Michael Goggins; Göran Hallmans; Susan E Hankinson; Judith A Hoffman Bolton; David J Hunter; Amy Hutchinson; Kevin B Jacobs; Mazda Jenab; Kay-Tee Khaw; Peter Kraft; Vittorio Krogh; Robert C Kurtz; Robert R McWilliams; Julie B Mendelsohn; Alpa V Patel; Kari G Rabe; Elio Riboli; Xiao-Ou Shu; Anne Tjønneland; Geoffrey S Tobias; Dimitrios Trichopoulos; Jarmo Virtamo; Kala Visvanathan; Joanne Watters; Herbert Yu; Anne Zeleniuch-Jacquotte; Laufey Amundadottir; Rachael Z Stolzenberg-Solomon
Journal:  Carcinogenesis       Date:  2012-04-20       Impact factor: 4.944

3.  Identification of circulating microRNAs in HNF1A-MODY carriers.

Authors:  C Bonner; K C Nyhan; S Bacon; M P Kyithar; J Schmid; C G Concannon; I M Bray; R L Stallings; J H M Prehn; M M Byrne
Journal:  Diabetologia       Date:  2013-05-15       Impact factor: 10.122

4.  Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines.

Authors:  K Terasawa; M Toyota; S Sagae; K Ogi; H Suzuki; T Sonoda; K Akino; R Maruyama; N Nishikawa; K Imai; Y Shinomura; T Saito; T Tokino
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.